CAPA In-vitro Oocyte Maturation
Chinese University of Hong Kong
100 participants
Nov 10, 2025
INTERVENTIONAL
Conditions
Summary
In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.
Eligibility
Inclusion Criteria3
- Patients aged from 0-50 years old
- Patients seek fertility preservation services
- Patients seek oocyte retrieval services
Exclusion Criteria1
- Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06984081